Trial Profile
An Open-Label, Randomized, Parallel-Group Study to Evaluate the Acute and Steady-State Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Captopril (Primary) ; Irbesartan
- Indications Hypertension
- Focus Pharmacodynamics
- Sponsors Novartis
- 28 Apr 2010 Actual patient number (45) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.